## Summary

The paper proposes an end-to-end multi-view diabetic retinopathy (DR) grading framework with two modules: Grade-Activated Lesion Proposal (GALP), which uses stage-wise auxiliary classifiers and grade-conditioned class-activation maps to select Top-K "lesion proposals," and Lesion Expert Guided Regional Fusion (LGRF), which fuses cross-view proposals via gated MoE plus Top-K-weighted cross-view attention. The method reports competitive results on MFIDDR (84.6% with lesion / 83.9% without) and DRTiD (76.0%), claiming to match or surpass externally-informed baselines without external annotations.

## Strengths

- **Annotation-free variant competitive with annotation-using baselines on MFIDDR.** Table 1 shows the lesion-free variant reaches 83.9% accuracy, surpassing all end-to-end baselines and matching/exceeding several externally-informed methods (CVSA 82.6, LFMVDR-with-lesion 82.2), which supports the practical claim about reducing annotation dependence.
- **Cleanest DRTiD result.** On DRTiD (Table 3), the end-to-end model reaches 76.0% accuracy, edging both CVSA (74.7, with vessel masks) and CrossFiT (75.6, with OD/macula coordinates), demonstrating the approach generalizes to a second benchmark without external supervision.
- **Each module is ablated and quantified.** Table 4 reports drops to 82.7 (w/o GALP), 82.6 (w/o Experts), 82.3 (w/o LGRF), demonstrating non-trivial contributions for each component.
- **Hyperparameter sweep is provided.** Figure 3 reports α, K₂, and M sweeps, identifying α=0.5, K₂=2, M=6 as the operating point.

## Weaknesses

### Fatal
None — no single flaw verifiably invalidates the contribution.

### Major

- **The "lesion proposal" interpretation is asserted but never validated, despite MFIDDR shipping lesion masks.** Sec. 3.2 explicitly frames Top-K peaks of the grade-conditioned evidence map as "lesion proposals" that act "as surrogates for external cues" and the abstract/intro repeatedly tie the contribution to recovering "small, low-contrast lesions." MFIDDR provides lesion segmentation masks (Sec. 4.1 acknowledges this — they are used for the "with lesion" SPADE variant). The obvious overlap metric (precision/recall or IoU between Top-K patches and labeled lesions, broken down by stage and lesion type) is never reported. Without it, what the paper demonstrates is that an auxiliary CAM-gated attention pipeline helps grading — not that CAM peaks correspond to lesions. This directly undercuts the contribution that distinguishes the work from generic auxiliary-head / CAM-attention methods.

- **The grade-wise pattern contradicts the motivating story.** The paper repeatedly motivates GALP by the failure of end-to-end models to capture microaneurysms and proliferative-DR-defining lesions (abstract, Sec. 1). In Table 2, "Ours (w/o lesion)" attains F1=36.0 on Grade 4 (proliferative DR — the class most defined by florid lesion content) versus CVSA 64.1 and SMVDR-W 40.8. Even with lesion fusion, Ours reaches 51.6, still well below CVSA's 64.1. The proposed method is strongest on Grades 0–3 and weakest where the motivating mechanism should pay off most, and the paper does not engage with this gap.

- **The GALP ablation conflates two effects.** GALP bundles (a) stage-wise auxiliary classification supervision — a known accuracy booster from deep-supervision literature — with (b) Top-K CAM proposal selection. The "w/o GALP" row in Table 4 removes both jointly, so one cannot tell whether the 1.2% accuracy gain comes from deep supervision or from the proposal mechanism that is purportedly the novelty. An ablation that retains aux loss but disables proposal selection (or vice versa) is essential given that the proposal interpretation carries the paper's identity (see Major #1).

- **Headline gains are within plausible run-to-run noise; no variance reported.** On MFIDDR, "Ours (with lesion)" beats SMVDR-M by 0.6% accuracy (84.6 vs 84.0) and WGLIN by 0.4% (vs 84.2); on DRTiD it beats CrossFiT by 0.4% (76.0 vs 75.6). No multi-seed mean±std, confidence intervals, or significance tests are reported. For sub-1% margins, multi-seed evaluation is standard in this literature and is needed before the "SOTA" framing in Sec. 4.2 / Sec. 5 is defensible.

### Minor

- **Cross-view fusion is limited to one cyclic neighbor.** Sec. 3.3 fuses view i only with j = (i mod N)+1. For 4-view MFIDDR this means each view sees evidence from exactly one other view. Given the paper's stated logic that cross-view corroboration is what makes self-derived proposals reliable, the lack of an all-pairs (or alternative pairing) ablation is a gap; even a brief comparison would clarify whether the architectural restriction is principled or convenient.

- **The "Ours (with lesion)" comparison mixes two changes.** SPADE-based image-level fusion of lesion masks (Sec. 4.1) is a different mechanism than the feature-side lesion guidance used in WGLIN/SMVDR/LFMVDR. Reading Table 1 as "Ours+lesion beats WGLIN" therefore conflates GALP/LGRF with the SPADE input pipeline. A controlled comparison (e.g., apply SPADE preprocessing to one baseline, or apply each baseline's lesion mechanism on top of the proposed architecture) is needed to attribute the 0.4–0.6% gain to the proposed method.

- **The proposal CAM is conditioned on the auxiliary head's predicted grade.** Eq. 3 uses class weights for the predicted grade ŷ at stage sₙ; if early-stage auxiliary classifiers misclassify (which is likely — those heads are deliberately shallow), proposals are conditioned on the wrong grade. A GT-class CAM variant or an analysis of how often the proposal grade matches the final prediction would address this.

### Trivial

- "matches or surpasses strong baselines without external annotations" (abstract) is too strong: on MFIDDR the lesion-free model is below WGLIN and SMVDR-M on Acc, Kappa, and F1. Reframing as "closes the gap with externally-informed methods" would be more accurate.

## Nice-to-Haves

- A direct test of whether Top-K patches overlap labeled lesions on MFIDDR (precision/recall by lesion type and by stage) would convert the central interpretive claim into a tested one and would be the single most strengthening addition.
- Disentangled GALP ablation (aux loss only vs. proposal-only vs. both).
- Multi-seed mean±std for both datasets, especially for the lesion-free vs. lesion-augmented contrast.
- An analysis of why Grade 4 performance lags — either acknowledging the limitation or reframing the motivation.
- Expert-utilization diagnostic for LGRF (e.g., routing entropy / per-grade expert usage) to show the MoE is doing meaningful routing rather than acting as a soft ensemble.

## Removed Points
These points are flagged to be removed, treat them with caution.

- **"Patch size q=7 at stage 4 yields a single patch, so Top-K is ill-defined" (Section-by-section note, Sec. 4.1):** The auxiliary loss in Eq. 2 sums n=1..3, so proposal generation operates over stages 1–3, not stage 4 (stage-4 features are used only via GAP for the final classifier per Eq. 17). The concern is partially obviated by what the paper already specifies.
- **"MoE under-justified, may behave like an ensemble" (Section-by-section note on Sec. 3.3):** Speculative — the ablation removing experts (Table 4, 83.9 → 82.6) does show the gated pool contributes, even if expert-specialization is not directly visualized. Demoted to a nice-to-have.
- Several Strength Finder claims about Grade 4 being "improved, especially with lesion input" and "best Grade 2 and Grade 3" are accurate locally but conflict with the verified weakness that Grade 4 still trails CVSA by ~13 F1 points even with lesion input — the weakness wins.

## Novel Insights
None beyond the paper's own contributions.

## Suggestions

- Add a Top-K-vs-lesion-mask overlap table on MFIDDR, broken down by stage and lesion type (microaneurysm / hemorrhage / exudate).
- Add ablations that decouple GALP's auxiliary supervision from its proposal selection.
- Run 3–5 seeds on both datasets; report mean±std for at least Acc, Kappa, F1, and the lesion-free vs. lesion-augmented contrast.
- Ablate cyclic-pairwise vs. all-pairs (or other connectivity) cross-view fusion.
- Apply SPADE preprocessing to one strong externally-informed baseline (e.g., WGLIN), or apply each baseline's lesion-guidance mechanism on top of GALP/LGRF, so the "with lesion" row attributes its gain cleanly.
- Soften the SOTA claim or add the controlled comparison that would substantiate it.

## Axis Evaluation

- **Originality:** Moderate. The architectural combination (stage-wise CAM-derived proposals + MoE-gated cross-view attention) is a sensible recombination, but neither component is conceptually new and the "self-derived = lesion" framing — the most novel claim — is not tested.
- **Importance of question:** Reasonably high. Reducing annotation dependence in multi-view DR grading is a real clinical concern.
- **Claim support:** Weakest axis. The headline lesion-proposal interpretation lacks validation despite available labels; gains are sub-1% without seed variance; ablation does not isolate the novel mechanism.
- **Soundness of experiments:** Acceptable methodology, two reasonable benchmarks, but missing variance reporting and key controlled comparisons (SPADE, cyclic vs. all-pairs).
- **Clarity:** Generally clear and well-structured; equations and architectural diagram are followable.
- **Value to community:** Useful as a competitive baseline that is end-to-end trainable, but the validation gap limits the credit the community can give to the "self-derived lesion" framing.

## Score Calibration

Anchors retrieved across rounds:

| Round | Path | Avg | Notes |
|---|---|---|---|
| 1 | 1P92J25hdf.md | 2.60 | Stereo matching, reject — clearly weaker than this paper. |
| 1 | EjIKerYk1O.md | 2.33 | Airside monitoring, reject — narrow application, weaker. |
| 1 | ZZVOrId3yN.md | 3.00 | Multimodal seg, reject — overclaims theory. Weaker. |
| 1 | ilGdLPy3mA.md | 3.40 | 3D patch ranking, reject — weaker rigor. |
| 1 | Sz2Ar6EqD5.md | 4.00 | Cross-modality MRI seg, reject — similar tier. |
| 1 | Lv9KZ5qCSG.md | 5.50 | Eye fairness dataset, reject — comparable polish and clinical relevance. |
| 1 | ittdt7tKND.md | 4.60 | DSPFusion, reject — application paper, unfair-comparison concern, similar tier. |
| 1 | 8g5Ye3c3oR.md | 4.50 | Weakly supervised lesion seg, reject — similar tier. |
| 1 | 3b9SKkRAKw.md | 8.00 | LeFusion, accept — substantially stronger contribution. |
| 1 | TPZRq4FALB.md | 8.00 | TTA multi-modal, accept — stronger conceptual novelty. |
| 1 | QQBPWtvtcn.md | 7.67 | LVSM view synthesis, accept — much stronger. |
| 1 | 5Ca9sSzuDp.md | 8.00 | CLIP interpretation, accept — much stronger. |
| 2 | uikf2Ue0XQ.md | 5.50 | Visual grounding, reject — comparable. |
| 2 | 7YEXo5qUmN.md | 4.67 | Organ-DETR, reject — comparable. |
| 2 | DcJuTtfYss.md | 5.75 | IA-DETR, reject — slightly above. |
| 2 | NJxCpMt0sf.md | 5.75 | Multi-modal MoE for medical, accept — directly comparable topic, slightly cleaner story. |
| 2 | 33P4evE2ej.md | 4.75 | DynaMer MoE adapter, reject — very comparable. |
| 2 | yVJd8lKyVX.md | 6.00 | Hybrid Sharing MoE, accept — better validated. |
| 2 | uWvKBCYh4S.md | 5.00 | Mixture of LoRA experts, accept — comparable score. |
| 2 | RJDjSXNuAZ.md | 5.50 | Weakly supervised virus detection, accept — comparable. |
| 2 | QG31By6S6w.md | 6.25 | 3D zero-shot lesion seg, accept — somewhat stronger. |
| 2 | 3b8CgMO5ix.md | 5.50 | Model guidance via explanations, reject — comparable. |

**Round-1 bracket:** Between 4 and 6. The paper is clearly above the 2–3.5 reject anchors (it has functional empirical results on two benchmarks and a real architectural contribution) but well below the 7.5+ accepts (which feature stronger novelty or validation).

**Round-2 narrowing:** The closest comparables are DSPFusion (4.60), DynaMer (4.75), Organ-DETR (4.67), Weakly Supervised Lesion Seg (4.50), and on the upper side Hybrid Sharing MoE (6.00) and the multi-modal MoE medical (5.75). The paper under review:
- Has cleaner empirical setup than DSPFusion/DynaMer (two relevant benchmarks, multiple baselines, an ablation that confirms each module).
- But is undermined by an unvalidated central interpretive claim with the means to validate it sitting in the dataset (Major #1) and contradictory grade-wise evidence (Major #2) — issues comparable in severity to the fairness-of-comparison flag in DSPFusion (4.6).
- Falls short of the multi-modal MoE medical paper (5.75), which has cleaner conceptual contribution and clearer validation.

This places the paper close to DSPFusion / DynaMer in the 4.5–5.0 range, slightly above the lesion-seg-GAN (4.5) anchor.

Final positioning: 4.5 — closer to the upper rejects than to the borderline accepts.

MY FINAL SCORE: <score>4.5</score>
MY FINAL DECISION: <decision>Reject</decision>